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ABSTRACT

Osteoporosis is a condition characterized by a reduction in bone strength resulting
in an overall increase in the risk of fracture. There are many factors that contribute to the
development of this condition, including ionizing radiation exposure. Declines in bone
volume and trabecular micro-architecture have been found following exposure to
multiple types of radiation. Past research has implicated reduction of osteoblast function
and changes to vasculature as the primary sources of bone deterioration. Recently, an
early increase in osteoclast number was observed following exposure to low-energy Xrays, identifying an increase in resorption as a possible cause and potential target for
treatment. The goals of this research are to further characterize the effects of X-rays on
trabecular bone at multiple skeletal sites and time points, and assess the effectiveness of
the bisphosphonate risedronate to mitigate the radiation-induced deterioration of the
trabecular network.
The results from this research indicate trabecular bone deterioration can occur
within the first week following exposure to ionizing radiation, with no effects on cortical
bone. Serum markers of bone resorption are elevated at 7 days, indicating an early
increase in osteoclast activity. Importantly, bisphosphonate administration prevents the
deterioration of trabecular bone volume and architecture at all time points and sites,
further supporting earlier findings of osteoclast-mediated bone loss.
In order to fully characterize the mechanisms resulting in bone loss, the radiationinduced changes to bone cells should be studied more closely along with effects on bone
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formation and resorption rates. Earlier time points within the first week post-irradiation
must be examined to determine the timeline when changes to bone cells produce
functional declines in bone volume and architecture. Additionally, the effects of these
declines need to be correlated with changes in overall bone strength in order to determine
the most appropriate dosing regimen for preventative and/or treatment therapies. The data
from these studies may be useful in determining the most effective method of preventing
fractures following radiotherapy.
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CHAPTER 1 - INTRODUCTION

Osteoporosis is a condition of reduced bone mass and overall bone quality,
leading to an increase in the risk of fracture. Bone quality encompasses both material and
structural properties, such as trabecular bone micro-architecture and collagen content
within the bone matrix. Degradation of the bone matrix and structure leads to an increase
in fragility and risk of fracture. Osteoporosis can affect all segments of the population,
though post-menopausal women are at the greatest risk. Estimates suggest 50% of
women and 25% of men over the age of 50 will suffer from an osteoporotic fracture.
Current treatments for osteoporosis include anabolic and anti-resorptive therapies.
Sex-hormone deficiency is the primary risk factor for osteoporosis, although
many other factors can contribute to its development, including exposure to ionizing
radiation. Ionizing radiation has been shown to degrade bone properties and increase
fracture risk through the inhibition of bone formation and damage to blood supply
pathways. Recent findings suggest an early increase in resorption may contribute to bone
loss. Standard osteoporosis treatments have not previously been used to prevent
radiation-induced bone loss. Indications of an osteoclast-regulated loss mechanism
suggest treatment with anti-resorptive drugs may prevent fractures. The goals of this
research are to characterize the effects of ionizing radiation on bone micro-architectural
properties, and examine the usefulness of anti-resorptive medications in preventing bone
deterioration.
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CHAPTER 2 - BACKGROUND

2.1 General Bone Biology
2.1.1 Components and Function
Bone is a composite connective tissue consisting of multiple cell types and an
extracellular matrix. This matrix consists primarily of type I collagen fibers (90%), as
well as other non-collagenous proteins and minerals. The collagen fibers are oriented
according to the direction of primary loading and provide tensile strength (Viguet-Carrin,
Garnero et al. 2006). The organic materials of the extracellular matrix are surrounded by
mineral crystals in the form of hydroxyapatite. These crystals attach to the collagen
fibers via the non-collagenous proteins, providing compressive strength and hardness.
Overall, the mineral crystals account for 70% of bone by mass, with the collagen fibers
and non-collagenous proteins accounting for 22%. The remaining 8% is attributed to
water (Augat and Schorlemmer 2006).
The skeletal system of mammals consists of two primary types of bone: woven
and lamellar. Woven bone is formed rapidly with no consistent orientation of collagen
fibers, resulting in a comparatively weak structure. This type of bone is common within
the developing fetus and functions as a place-holder during the fracture repair process
(Currey 2003). Woven bone is eventually replaced with lamellar bone. Lamellar bone is
organized into sheets of collagen and minerals and is much stronger than woven bone.
Mature lamellar bone exists in two primary forms: cortical (80%) and trabecular
(20%). Cortical bone is highly mineralized and comparatively static in terms of turnover
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and remodeling. It is present within the outer shell of all bones and the diaphyses of long
bones. In higher order mammals, the basic unit of organization is the osteon, which
consists of multiple concentric layers of bone surrounding a vascular (Haversian) canal.
The diaphyses of long bones are composed of many continuous, circumferential lamellae
(Figure 2.1).

Figure 2.1. Basic cortical bone structure.
(http://www.mc.vanderbilt.edu/histology/labmanual2002/labsection1/CartilageandBone0
3_files/image002.jpg)

Trabecular (cancellous or spongy) bone is a micro-architectural lattice-work of
small, interconnected struts found in the interior of bones (Figure 2.2). This type of bone
is most abundant in the epiphyses and metaphyses of long bones, and is present
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throughout the interior of the cortical shell of flat bones. Individual struts are typically
structured as rods or plates, depending on the loading conditions. Trabecular bone has a
higher turnover rate than cortical bone and is significantly less mineralized (Heaney
2003). Accordingly, it is generally much more porous than cortical bone. The
percentage breakdown of cortical and trabecular bone varies throughout the skeleton. For
instance, the epiphyses and metaphyses of long bones contain much more trabecular bone
than the diaphyses, which are almost entirely cortical bone.

Figure 2.2. Trabecular (cancellous) bone.
(http://www.ama-cmeonline.com/osteo_mgmt/module03/images/m3_02path_02.jpg)

The skeletal system has several important functions. Bones, along with muscles,
provide the structural and mechanical framework necessary for movement and support of
the body. The skeleton also plays a vital role in the protection of the body’s organ
systems. The ribs provide a protective framework for the heart and lungs while the skull
protects the central component of the nervous system. Bone is also responsible for
storing the majority of the body’s supply of calcium. Calcium is an important mineral
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involved with many physiological activities, including muscle contraction. The
hydroxyapatite crystals of the bone extracellular matrix contain approximately 99% of
the body’s total calcium supply. As it is needed, calcium is released into the blood
stream and distributed to the appropriate regions of the body (Specker 1996). Lastly, the
intramedullary cavities of long bones provide a protective environment for marrow and
blood cell formation.

2.1.2 Bone Remodeling
Bone is a dynamic connective tissue capable of self-maintenance and self-repair.
In the normal, healthy skeleton, old and damaged bone is constantly being resorbed and
replaced with new bone. This continuous cycle of resorption and formation is referred to
as remodeling. Osteoclasts and osteoblasts are the key cells involved in the remodeling
process. Osteoclasts are responsible for breaking down old or damaged bone. The
resorptive activity of these cells triggers the action of osteoblasts, which form new bone
within the resorption cavity.

2.1.2.1 Resorption Activity by Osteoclasts
Osteoclasts are large, multinucleated cells responsible for the removal of old or
damaged bone. These cells arise from the precursors of the monocyte/macrophage cell
line (Blair, Zhou et al. 2006). Typically, osteoclasts are positioned in contact with the
mineralized bone surface. The primary identifying feature of osteoclasts is the ruffled
border, a folding of plasma membranes in direct contact with the bone matrix. This
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border is surrounded by an actin protein ring which attaches to the bone surface and
effectively seals off the region of bone to be resorbed (Vaananen, Zhao et al. 2000).
Proton pumps create an acidic environment by releasing hydrogen ions along with
lysosomal enzymes (tartrate-resistant acid phosphatase, cathepsin K, etc.) into the
resorption compartment (Vaananen, Zhao et al. 2000). The enzymes digest the collagen
and bone matrix within the sealed region. Hydroxyapatite crystals are dissolved by the
acid environment (Zaidi, Pazianas et al. 1993). The dissolution of the bone matrix forms
a resorption cavity referred to as a Howship’s lacuna (Figure 2.3).

Figure 2.3. Osteoclast within a Howship’s lacuna.
(http://herkules.oulu.fi/isbn9514267761/html/graphic66.png)

2.1.2.2 Formation of Bone by Osteoblasts
Osteoblasts are cells that typically line the surface of bone and are responsible for
the formation of new bone. These cells arise from mesenchymal stem cells within the
bone marrow. Progenitor cells differentiate into pre-osteoblasts and ultimately, mature
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osteoblasts under the regulation of cytokines and growth factors (Lian and Stein 1995).
Osteoblasts lining bone surfaces are directly connected, allowing communication
between individual cells (Stains and Civitelli 2005). Osteoblasts are activated via a
signal once bone resorption at a site is complete. New, un-mineralized bone matrix
(osteoid) is laid down within the resorption cavity. The new matrix begins to mineralize
over the next 5-10 days, and continues to do so until approximately 60% of the cavity is
filled. Secondary mineralization then begins and can continue for years thereafter
(Davison, Siminoski et al. 2006). Once the formation process is complete, the majority
of osteoblasts die via apoptosis. Others become trapped within the bone matrix during
the mineralization process, becoming osteocytes. Osteocytes are responsible for the
maintenance of bone and exist within lacunae or along the quiescent surface of bone.
These cells communicate with each other and with surface-lining osteoblasts, playing a
vital role in the mineralization process as well as the bone matrix response to mechanical
loading (Rodan 1992).

2.1.2.3 Remodeling Process
The bone remodeling process consists of five primary stages: quiescence,
activation, resorption, reversal, and formation (Parfitt 1984). The resting state of bone is
referred to as quiescence. The surface of the bone is lined with flattened osteoblasts.
Upon activation of the remodeling mechanisms, the surface-lining cells retract and
expose the bone surface. Circulating pre-osteoclasts are attracted to the exposed surface
and fuse into mature, multinucleated osteoclasts. The osteoclasts are then activated and
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begin the resorption process. Once resorption is complete, osteoblasts are signaled and
converge at the resorption site to begin laying down new osteoid. The new bone matrix
becomes mineralized over time and the bone surface returns to the quiescent state (Figure
2.4).

Figure 2.4. Bone remodeling cycle.
(http://www.umich.edu/news/Releases/2005/Feb05/bone.html)

The remodeling process is regulated by many molecular elements, such as
hormones, cytokines, and growth factors along with bone cells (osteoclasts, osteoblasts)
(Mundy 1993; Fernandez-Tresguerres-Hernandez-Gil, Alobera-Gracia et al. 2006). In
healthy individuals, remodeling is balanced between resorption and formation, as
approximately 2% of cortical bone and 15-20% of trabecular bone is renewed each year,
giving an overall rate of 5-10% (Fernandez-Tresguerres-Hernandez-Gil, Alobera-Gracia
et al. 2006). In normal remodeling, the resorption process is always followed by the
formation of new bone. As such, stimulation or inhibition of either of these processes
results in a similar response in the other process. Disruption of this balance results in the
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onset of many skeletal diseases, including osteoporosis, osteopetrosis, Paget’s disease,
and malignant bone metastases (Blair, Zhou et al. 2006).

2.1.3 Biomechanics of Bone
Bone plays an important role as the structural framework for support and
movement of the body. Individual bones function as levers for muscle contractions and
provide support during movement. Strength is the key measure of bone functionality
within biomechanics and serves as the primary indicator of fracture susceptibility (Turner
2002). Bone strength is influenced by several factors, including overall mass, material
properties, and structural properties (micro-architecture, moment of inertia, etc.)
(Ammann and Rizzoli 2003; Bouxsein 2005; Augat and Schorlemmer 2006). In the
clinical setting, measures of bone mineral density as determined using dual-energy X-ray
absorptiometry (DEXA) are used to estimate strength. DEXA alone, however, does not
correlate directly to whole bone strength. Estimates indicate mineral content and porosity
account for only 60% of bone bending strength (Currey 1999). The remaining percentage
is determined by a combination of material and structural properties. These properties
are collectively referred to as ‘bone quality’ and, along with the rate of remodeling, must
be considered in order to accurately estimate bone strength (Burr 2004).

2.1.3.1 Bone Material Properties
Bone is a composite tissue composed primarily of type I collagen (22%) and
mineral crystals (70%) (Augat and Schorlemmer 2006). Reductions in collagen quality
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have little to no effect on the elastic modulus of bone or stiffness. However, collagen
plays a vital role in the inhibition of crack propagation. Accordingly, toughness (energy
absorbed to fracture) and tensile strength are positively correlated to collagen quality.
Reduction in quality has a significant negative impact on these parameters (Burr 2002).
The stability and cross-linking of the collagen fibers also affect strength, as studies have
shown a positive correlation between the number of cross-links and overall toughness
(Zioupos, Currey et al. 1999). The extent of collagen cross-linking decreases with age,
leading to an increase in fracture susceptibility (Zioupos, Currey et al. 1999). The
stiffness of bone is directly proportional to the degree of mineralization (Bouxsein 2005).
The mineral crystals within bone are primarily in the form of hydroxyapatite
(Ca10(PO4)6(OH)2). These crystals nucleate within the collagen fibrils, and their size and
distribution directly affect density and strength. The size of the crystals tends to increase
with age, causing bone to become more brittle (Augat and Schorlemmer 2006).
In healthy bone, the ratio of mineral and collagen content is sufficient to
withstand normal loading within everyday life. However, deviations in the degree of
mineralization can lead to negative effects on bone strength. A low turnover rate causes
bone to become hyper-mineralized and damage to accumulate within the matrix. With
suppressed remodeling, the bone material becomes more homogeneous, allowing cracks
to propagate more easily than otherwise (Augat and Schorlemmer 2006). This leads to a
decrease in toughness and ultimate strain when loaded in tension (Currey, Brear et al.
1996; Augat and Schorlemmer 2006). Increases in turnover can be equally as harmful,
albeit for different reasons. High turnover rates lead to hypo-mineralized bone.
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Toughness and tensile strength are increased, but stiffness is greatly reduced, as seen in
individuals suffering from osteomalacia or rickets.

2.1.3.2 Bone Structural Properties
The distribution of mass plays an important role in the determination of bone
structural properties. In the simplest terms, bigger is better, meaning large bones are
generally capable of supporting large loads (Bouxsein 2005). However, without
accounting for the distribution, bone mass alone is not a direct indicator of strength. The
thickness of the cortical shell, cross-sectional area, and moment of inertia have been
shown to account for up to 70% of whole bone strength (Augat and Schorlemmer 2006).
The ability of bone to resist bending and torsional loading is directly proportional to
moment of inertia. Polar moment of inertia is often used to indicate strength, as it takes
into account the distribution of mass relative to both cross-sectional axes. While keeping
cross-sectional area constant, increasing the diameter of a bone distributes mass farther
from the neutral axis (higher moment of inertia) and increases the maximum bending
load that can be applied without failure (Figure 2.5). As such, a small diameter bone with
a thick cortical shell is not necessarily the optimum structural configuration.
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Figure 2.5. Illustration of geometric influences on bone strength. (Bouxsein 2005)

The micro-architecture of trabecular bone is also a key component in bone
strength determination. Trabecular bone is a highly porous, interconnected lattice-work
of struts. These struts are typically structured as either cylindrical rods or parallel plates,
and are important in the distribution of forces throughout the bone structure. Trabecular
bone is found within the epiphyses and metaphyses of long bones and within the cortical
shell of flat bones. Common measures of trabecular bone micro-architecture include
bone volume fraction (BV/TV), connectivity density, structural model index (SMI),
trabecular number, trabecular thickness, and trabecular separation. Trabecular volume
fraction, connectivity density, and structural model index measure properties of the entire
trabecular structure. Trabecular number, thickness, and separation are associated with
individual struts.
Bone volume fraction is a percentage measure of the amount of trabecular bone
present. Together with density, bone volume is a strong indicator of overall strength
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(Keaveny and Hayes 1993; Currey 2001). Connectivity density measures the number of
trabecular connections per unit volume. Qualitatively, connectivity is important in the
efficient transfer of loads throughout the bone structure (Figure 2.6). High connectivity
indicates the majority of struts within the network are supported (Borah, Gross et al.
2001). The strength of a strut is inversely proportional to the square of the unsupported
length (Davison, Siminoski et al. 2006), meaning strength increases with connectivity.

Figure 2.6. Connectivity of trabecular bone.
(http://www.designfax.net/archives/0904/IMAGES/D0409-141a-big.gif)

Loss of individual struts reduces connectivity and strength. The removal of
horizontal struts is particularly damaging, as the likelihood of buckling failure of the
remaining vertical struts becomes increased (Bouxsein 2005) (Figure 2.7). Trabecular
number and separation are closely associated with connectivity, as a reduction in number
will likely lead to a reduction in connectivity and an increase in separation. Trabecular
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thickness has a smaller effect on strength (Bouxsein 2005), and is related more closely to
the structural model index.

Figure 2.7. Effect of trabecular struts on buckling strength. (Bouxsein 2005)

Structural model index measures the ratio of rod-like to plate-like trabeculae.
Bone volume fraction is negatively correlated with SMI, as regions of high trabecular
bone volume typically have a higher number of thick, plate-like trabeculae (lower SMI)
(Hildebrand, Laib et al. 1999). Accordingly, lower values of SMI are associated with
higher measures of bone strength. Trabecular thickness tends to decrease as plate-like
elements are restructured as rod-like. As mentioned earlier, trabecular thinning is not as
harmful to strength as is the complete removal of a trabecular strut. However, an
increase in SMI coupled with a decrease in trabecular thickness can be indicative of bone
loss associated with osteoporosis (Borah, Dufresne et al. 2004).
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2.1.3.3 Turnover Influence on Biomechanics
The rate of bone remodeling has a substantial effect on bone quality (Heaney
2003). Under normal circumstances, bone resorption and formation are balanced,
ensuring sufficient strength to withstand normal loading is maintained. If this balance is
disrupted, harmful changes in bone material and structural properties occur, as seen in
aging individuals or those suffering from a skeletal disease. Non-normal rates of
remodeling, whether high or low, compromise overall bone strength. Elevation of the
normal bone turnover rate produces an increase in resorption, decrease in mass and
mineralization, and a net reduction in bone strength (Parfitt 2002; Heaney 2003; Borah,
Dufresne et al. 2004). An extreme case of this mechanism is manifested as Paget’s
disease. Paget’s disease is characterized by an abnormally high rate of bone turnover,
resulting in the formation of irregular woven bone and an overall increase in density.
However, as woven bone is overly ductile and generally weaker than lamellar bone,
skeletal strength is greatly compromised (Raisz 1999).
A lower than normal turnover rate adversely affects bone in other ways. Normal
remodeling is necessary for the repair of micro-fractures and the renewal of old, brittle
bone. Turnover suppression leads to the accumulation of damage within the bone matrix
and allows older bone to become hyper-mineralized, reducing the overall quality and
strength of the bone. This mechanism is most clearly identified with osteopetrosis, a
disease characterized by overly dense, brittle bones (Tolar, Teitelbaum et al. 2004).
Osteopetrosis is induced by a loss or impairment of osteoclast function resulting in
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abnormal architecture (Raisz 1999). As a result, individuals afflicted with osteopetrosis
are generally much more susceptible to fracture than those with normal bone.

2.2 Osteoporosis
Osteoporosis is a skeletal condition of reduced bone mass coupled with
degradation of micro-architectural properties (Figure 2.8), resulting in overall weaker
bones and an increase in fracture susceptibility (Consensus development conference
1993; NIH Consensus Development Panel 2001). Osteoporotic fractures typically occur
in the absence of trauma, and are most common at the hips, spine, and wrists. Measures
of bone mineral density are the primary tool used for clinical diagnosis. Individuals with
bone density scores more than 1 standard deviation below the mean for a young adult are
classified as ‘at risk’ for the disease, while results more than 2.5 standard deviations
below the mean indicate the patient has osteoporosis.

Figure 2.8. Comparison of normal and osteoporotic bone. (Dufresne, Chmielewski et al.
2003)

16

Osteoporosis is a major public health concern. The condition currently affects
more than 10 million Americans with another 34 million classified as ‘at risk’ (National
Osteoporosis Foundation 2008). Approximately 50% of women and 25% of men over
the age of 50 will suffer from an osteoporotic fracture within their lifetime. The number
of fractures related to osteoporosis is expected to reach 3 million per year by 2025
(National Osteoporosis Foundation 2008). These fractures are often treated with invasive
surgeries, leading to high levels of morbidity and mortality, particularly in the case of hip
fractures. Nearly ¼ of hip fracture patients die within the first year following fracture,
and only 15% are able to walk across a room unaided at 6 months (National Osteoporosis
Foundation 2008). Many patients require long-term care, creating a large financial
burden on both the healthy and afflicted populations.

2.2.1 Mechanisms of Osteoporosis
There are many risk factors for osteoporosis, including menopause, aging, and
glucocorticoid therapies. Glucocorticoids are used as strong anti-inflammatory agents.
These drugs have been shown to reduce bone strength by suppressing formation (Lems
2007). Apoptosis of osteocytes and osteoblasts is induced, severely limiting the
production of the organic bone constituents.
Estrogen deficiency has been implicated as the primary cause of osteoporosis in
post-menopausal women and a contributor to development of the condition in men
(Riggs, Khosla et al. 2002). Reduction in estrogen production unbalances the normal
turnover mechanism in the direction of resorption, leading to substantial bone loss. The
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rise in resorption levels results from an overall increase in osteoclast production and
activity (Manolagas 2000). This increase in osteoclast activity can lead to an increased
turnover rate, deep resorption lacunae, and deterioration of trabecular bone microarchitecture. Specifically, trabecular plates become perforated and disconnected as they
are restructured into rods. Osteocytes and osteoblasts are also affected by lower estrogen
levels. The survival rate of osteocytes decreases, as does the ability of osteoblasts to
detect and repair micro-fractures (Manolagas 2000).
Regardless of cause, osteoporosis tends to worsen with age. The body’s ability to
respond to skeletal injury decreases with age, leading to the accumulation of microfractures and an increase in porosity throughout (Schaffler, Choi et al. 1995). Osteoblast
recruitment to damage sites is markedly reduced, allowing micro-damage to accumulate
more rapidly than the repair processes can handle. Micro-architectural deterioration
continually decreases, as does whole bone strength (Schaffler, Choi et al. 1995).

2.2.1.1 Radiation-Induced Osteoporosis
Humans are exposed to radiation from background sources throughout their lives.
The received doses, however, are typically not large enough to produce significant health
problems (Todd 2003). Exposure to large doses, such as those used in cancer
radiotherapy, is potentially very damaging to many of the body’s systems, including the
skeletal system. Nearly 1.5 million new cases of cancer are expected in 2008, along with
over 500,000 deaths. Approximately 60% of all cancer patients will undergo
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radiotherapy, placing an increasingly large segment of the population at risk to the sideeffects of radiation exposure.
Fracture following radiotherapy is a well-documented phenomenon. Fractures at
multiple sites throughout the body have been noted following radiation therapy, including
the hips, ribs, clavicle, and humerus (Howland, Loeffler et al. 1975; Pierce, Recht et al.
1992; Grigsby, Roberts et al. 1995; Bliss, Parsons et al. 1996; Mumber, Greven et al.
1997; Moreno, Clemente et al. 1999). Additionally, the relative risk of fracture within
the radiation-treated population is much higher (Baxter, Habermann et al. 2005).
Deterioration of trabecular bone micro-architecture has been found in rodents following
exposure to several types of radiation, including those used in the clinical setting (gamma
rays, protons) (Hamilton, Pecaut et al. 2006; Bandstra, Pecaut et al. 2008), as has reduced
bone mineral content in humans (Nishiyama, Inaba et al. 1992). Micro-architecture and
mineral content are both key components to whole bone strength (Ammann and Rizzoli
2003; Bouxsein 2005; Augat and Schorlemmer 2006). As such, the loss of either can
have a substantial negative impact on strength.
The mechanisms leading to the noted loss of bone are not yet fully identified, and
are currently under investigation within our laboratory. Past research identifies reduced
osteoblast functionality and damage to vasculature as the root causes of bone
deterioration (Mitchell and Logan 1998; Okunieff, Wang et al. 1998; Gal, MunozAntonia et al. 2000; Sakurai, Sawada et al. 2007). A recent study within our laboratory
suggests osteoclast activity is increased following irradiation (Willey et al. Radiat Res,
accepted 6/08). These findings will be explored further within the next chapter.
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2.2.2 Osteoporosis Treatments
The ultimate osteoporosis treatment goal is to build new bone with normal
structure and quality (Rizzoli 2007). Currently, there are two primary types of treatment
available for osteoporosis: anti-resorptive and anabolic therapies. Anti-resorptives
function by inhibiting osteoclast resorptive ability. Anabolic treatments induce bone
formation. With the identification of decreased sex hormone production as the primary
cause of osteoporosis, some type of hormone replacement therapy would seem to be the
obvious method of treatment. However, a rise in the risk of breast cancer and
cardiovascular diseases has been linked to hormone replacement therapy (Couzin 2003).
Anti-resorptives, namely bisphosphonates, are the most common osteoporosis treatments
currently used.

2.2.2.1 Anti-resorptive Therapy (bisphosphonates)
Bisphosphonates function by binding to the exposed mineral surface of bone
(Rogers, Watts et al. 1997). Bone resorption is affected in several ways.
Bisphosphonates disrupt the ability of resorbing cells to attach to the bone surface
effectively (Rogers, Watts et al. 1997). The ruffled border of the osteoclast becomes
unable to form a seal with the bone surface, allowing the secreted mineral-dissolving
solution to leak away from the bone (Azuma, Sato et al. 1995). In addition,
bisphosphonates have been shown to act directly on osteoclasts. The drug is internalized
by osteoclasts and can severely limit the resorptive capability of the cell or induce
apoptosis (Azuma, Sato et al. 1995; Rogers, Watts et al. 1997). Bisphosphonates have
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also been shown to negatively affect osteoclast differentiation and recruitment to bone
surfaces (Azuma, Sato et al. 1995; Rodan and Fleisch 1996; Rogers 2003). It has
recently been suggested that osteoblasts and osteocytes are also affected by
bisphosphonates. Small concentrations have been shown to stimulate osteoblasts and
inhibit osteocyte apoptosis, although the effects on osteoblasts are likely due to the
normal coupling mechanism of osteoblasts and osteoclasts (Russell, Watts et al. 2008).
Clinically, bisphosphonates are known to have positive effects on bone turnover,
mineralization, micro-architecture, and fracture risk (Borah, Gross et al. 2001; Borah,
Dufresne et al. 2004; Rizzoli 2007). However, prolonged use can also inhibit formation.
Upon binding to the bone mineral surface, bisphosphonate molecules can remain within
the skeletal system for several years. The anti-resorptive effects have been demonstrated
for 5 years following the cessation of a 5-year treatment regimen (Rizzoli 2007). Longterm accumulation has the potential to severely inhibit the normal bone turnover
mechanism, resulting in overly porous and fragile bone.

2.2.2.2 Anabolic Therapy
Recombinant human parathyroid hormone (rhPTH) was approved by the FDA as
an anabolic treatment option in 2002. The drug functions by stimulating bone formation
on previously quiescent bone surfaces. Anabolic therapy is typically used only in
patients who already have multiple osteoporotic fractures (Benhamou 2007). Increases in
bone mineral density in the lumbar spine (9-13%) and femoral neck (3%) have been
noted in post-menopausal women following PTH therapy (Neer, Arnaud et al. 2001).
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Positive effects within trabecular bone have also been observed (Dempster, Cosman et al.
2001). PTH therapy can also significantly reduce the risk of both vertebral and nonvertebral fractures (Neer, Arnaud et al. 2001). PTH is not an ideal therapy for
osteoporosis, however. Administration currently requires a daily subcutaneous injection,
which is much more inconvenient to the patient than the standard oral doses of
bisphosphonates. In addition, PTH stimulates osteoclast function through the normal
coupling mechanism of osteoblasts and osteoclasts. The associated increase in bone
resorption at least partially inhibits the positive effects on bone formation and strength
(Fu, Jilka et al. 2002).
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CHAPTER 3 - THE USE OF RISEDRONATE AS A COUNTERMEASURE TO
RADIATION-INDUCED BONE LOSS

3.1 Abstract
Bone loss is a known side-effect of exposure to ionizing radiation. Recently, an
early increase in osteoclast activity was identified as a possible cause of radiation
atrophy. In this study, mice were exposed to a 2 Gy whole-body dose of X-rays to
quantify effects on trabecular micro-architecture and examine the effectiveness of
bisphosphonate administration at mitigating bone loss. C57Bl6/J mice were sacrificed at
one, two, and three weeks post-irradiation. Within each time point were three groups:
non-irradiated controls, irradiated given placebo, and irradiated given risedronate
(Actonel®; Procter and Gamble Pharmaceuticals). Analysis using microCT found
significant declines in trabecular bone volume and architectural properties at all time
points within the tibia, femur, and fifth lumbar vertebra. Serum levels of tartrate-resistant
acid phosphatase (TRAP5b), a marker of bone resorption, were elevated at one week. No
changes were found in serum osteocalcin levels or cortical bone properties of the femoral
mid-diaphysis. Risedronate administration prevented trabecular bone deterioration at all
sites and time points examined, and significantly reduced TRAP5b concentration to
below-normal levels. These findings support the hypothesis of an early, radiationinduced increase in osteoclast activity, and provide the basis for a potential method of
prevention of post-irradiation fractures.
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3.2 Introduction
Osteoporosis is a result of declines in density as well as significant deterioration
of the micro-architectural properties of bone, leading to increased fracture risk
(Consensus development conference 1993; NIH Consensus Development Panel 2001).
Although menopause is the greatest risk factor for osteoporosis, many other factors
contribute to the etiology of this condition (NIH Consensus Development Panel 2001;
National Osteoporosis Foundation 2008). Among these factors may be the relatively
unexplored effect of ionizing radiation on skeletal properties.
Radiation therapy has been linked to fractures at several skeletal sites, including
the clavicle, humerus, ribs, and pelvis (Howland, Loeffler et al. 1975; Pierce, Recht et al.
1992; Grigsby, Roberts et al. 1995; Bliss, Parsons et al. 1996; Mumber, Greven et al.
1997; Moreno, Clemente et al. 1999). The vast majority of these fractures have been
documented in the hip. Baxter et al. found a marked increase in the rate of hip fracture in
post-menopausal women receiving radiation treatment for pelvic tumors (Baxter,
Habermann et al. 2005). This is particularly alarming, as from this demographic, hip
fractures can result in substantial morbidity, loss of independence, and approximately a
15-20% mortality rate within the first year of injury (NIH Consensus Development Panel
2001; National Osteoporosis Foundation 2008).
The incidence of hip fractures following radiotherapy is a great concern, as
improvements in diagnosis and treatment are increasing the 5 year cancer survival rate.
In 2008, an estimated 500,000 new cases of pelvic cancers will be diagnosed. Of these
new cases, approximately 60% will receive radiation therapy (National Cancer Institute
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2007). Therefore, the possibility that ionizing radiation can directly serve as a cause of
pathological bone loss or reduced quality of bone should be explored.
Atrophy following irradiation has been documented as a late response in clinical
studies (Nishiyama, Inaba et al. 1992) as well as animal trials using clinically-relevant
types of radiation at relatively low (i.e. 1 Gy protons), acute doses (Hamilton, Pecaut et
al. 2006; Bandstra, Pecaut et al. 2008). Much of the research to date has focused on
damage to vasculature and bone-forming cells (Mitchell and Logan 1998; Okunieff,
Wang et al. 1998; Gal, Munoz-Antonia et al. 2000; Sakurai, Sawada et al. 2007).
Significant reduction in blood flow to irradiated regions has been documented (Okunieff,
Wang et al. 1998). This reduction in flow may contribute to long-term bone damage,
including atrophy (Mitchell and Logan 1998; Hopewell 2003). It is believed that the
function of osteoblasts is impaired sufficiently to inhibit the production of bone
extracellular matrix (Mitchell and Logan 1998). A significant reduction in bone
formation coupled with an increase in resorption following high-dose irradiation has been
observed (Sugimoto, Takahashi et al. 1991), as well as decreased osteoblast number,
proliferation, differentiation, and collagen production from both in vivo and in vitro
models (Gal, Munoz-Antonia et al. 2000; Sawajiri, Mizoe et al. 2003; Ma, Shi et al.
2007; Sakurai, Sawada et al. 2007).
At present, few researchers have studied radiation effects on osteoclasts, and the
results from those who have are inconsistent. Sawajiri et al. observed a long-term
decrease in osteoclast numbers following high-dose irradiation with carbon ions and
gamma rays, with inconclusive results in the short-term (Sawajiri, Mizoe et al. 2003).
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Others have noted no change in osteoclast numbers following irradiation (Goblirsch,
Mathews et al. 2004; Vit, Ohara et al. 2006). Recently, significant increases in osteoclast
number and activity have been observed following a whole-body dose of X-rays at 3 days
post-irradiation, though without a loss of bone volume or trabecular parameters as
quantified via micro-computed tomography (Willey et al. Radiat Res, accepted 6/08). An
acute increase in osteoclast activity may at least contribute to long term bone atrophy.
This connection between early osteoclast activation and radiation atrophy would provide
a potential pharmacological target for treatment using bisphosphonates, specifically
risedronate (Actonel®; Procter and Gamble Pharmaceuticals).
Bisphosphonates are currently the most common drugs used in the treatment of
osteoporosis. These drugs function by lessening bone turnover through the inhibition of
osteoclast activity (Russell 2007). Bisphosphonates have been shown as an effective
treatment option for hypercalcemia, fractures, bone pain, and other bone-related problems
associated with cancer (Guise and Mundy 1998; Body and Mancini 2002; Ross, Saunders
et al. 2003; Russell 2007). If radiation were to induce an early increase in osteoclast
activity, the action of bisphosphonates may prevent subsequent post-exposure atrophy.
The aims of this research were to: a) characterize the early effects of ionizing radiation
on bone properties by examining multiple time points and skeletal sites, and b) evaluate
the effectiveness of risedronate at preventing the osteoclast-mediated degradation of bone
micro-architecture.
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3.3 Methods
3.3.1 Animals and Study Design
One hundred fifteen 20-week-old female C57BL/6 mice (Taconic Farms, Inc.,
Hudson, NY) were examined in this study. The mice were received at 15 weeks of age
and allowed to acclimatize to their environment and reach skeletal maturity at 20 weeks
of age (Ferguson, Ayers et al. 2003). The animals were grouped to control for body
mass. Ten groups were studied (n=10-12 per group). In addition to baseline controls
(n=10), groups of mice were euthanized at one (n=36), two (n=36), and three (n=33)
weeks following radiation exposure. Within each time point, mice were divided evenly
into three treatments: non-irradiated given placebo (NR+PL), irradiated given placebo
(IR+PL), and irradiated given risedronate (IR+RIS). All subsequent procedures were
approved by the Institutional Animal Care and Use Committee at Clemson University.

3.3.2 Treatments: Irradiation and Risedronate
The mice in the IR+PL and IR+RIS groups were exposed to a dose of X-rays
using a portable industrial unit (Philips K140Be) operating at 140 kVp. All mice were
anesthetized prior to exposure with isoflurane. Mice in the radiation groups were placed
4.4 cm below the shield of the X-ray source and exposed to a 2 Gy whole-body dose at a
rate of 1.36 Gy/min. Non-irradiated mice were kept under anesthesia for an equivalent
period of time. Beginning on the day of irradiation, each animal in the study groups
received a subcutaneous injection of either risedronate (Actonel®; Procter and Gamble
Pharmaceuticals) or placebo (PBS) every other day. Each mouse in the IR+RIS groups
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received a dose of 30 µg/kg body mass every other day. Mice in the NR+PL and IR+PL
groups received an equivalent volume of PBS.
The baseline control animals were sacrificed the day following the radiation
exposures. The remaining animals were sacrificed at 1, 2, or 3 weeks following radiation
exposure. At the time of sacrifice, each mouse was anesthetized using isoflurane. Blood
was collected for serum analysis by cardiac puncture and exsanguination followed by
cervical dislocation to ensure death. The left hind limb and vertebral column were
collected for trabecular and cortical bone analysis. The left hind limb was stored in a
10% formalin solution. The vertebral column was frozen in saline-soaked gauze

3.3.3 Bone Architectural Analyses
After 48 hours, the left hind limb was removed from formalin solution and stored
in 70% ethanol, with the femur and tibia cleaned of nonosseous tissue. The tibiae were
then analyzed using micro-computed tomography (µCT20; Scanco Medical AG,
Bassersdorf, Switzerland). A section of each tibia immediately distal to the epiphyseal
plate measuring approximately 1 mm was scanned with a 9 µm voxel size. Threedimensional images were reconstructed from all scans and used to evaluate trabecular
bone properties. Trabecular bone volume fraction (BV/TV), connectivity density
(Conn.Dens), structural model index (SMI), trabecular thickness (Tb.Th), trabecular
number (Tb.N), trabecular spacing (Tb.Sp), and bone mineral density (vBMD) were
measured for each sample using Scanco analysis software.
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The fifth lumbar vertebrae and femora analyses were performed similarly using
microCT (µCT80; Scanco Medical AG, Bassersdorf, Switzerland). The collected
vertebra samples were removed from frozen storage and placed in ethanol solution. The
fifth lumbar vertebra was isolated using the microCT X-ray scout view and scanned in its
entirety (~3.5 mm) with a 10 µm voxel size. A section of the vertebral body measuring
0.5 mm immediately superior to the caudal end plate was selected for analysis. This
region was chosen because of its relatively high trabecular bone density and to minimize
morphological differences between samples. Trabecular bone properties were evaluated
for each sample. The left femora were evaluated in 2 regions: the distal metaphysis and
the mid-diaphysis. A 1 mm section immediately superior to the distal growth plate was
scanned and used to evaluate trabecular bone properties. A section of the mid-diaphysis
measuring approximately 0.3 mm was scanned and evaluated to determine cortical bone
volume (BV), cortical porosity (Ct.Po), and polar moment of inertia (pMOI).

3.3.4 Serum Chemistry
The collected serum samples were analyzed for markers of bone formation and
resorption using ELISA kits for osteocalcin (Biomedical Technologies, Inc., Stoughton,
MA) and tartrate-resistant acid phosphatase (TRAP5b) (Immunodiagnostic Systems, Inc.,
Fountain Hills, AZ), respectively. The analyses were performed according to protocols
provided by the manufacturers.
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3.3.5 Statistical Evaluation
All data are presented as mean ± standard error of the mean. Significance was
determined using SigmaStat version 3.5 (Systat Software Inc., Richmond, CA). A oneway analysis of variance with a Tukey post-hoc test was run on all results within each
time point and across the duration of the study within NR+PL, IR+PL, IR+RIS. Animal
masses were evaluated further using a paired t-test to determine changes in animal mass
for an individual group during the period of study. The threshold for significance for all
tests was set at a 5% probability of committing a Type I error (p=0.05).

3.4 Results
3.4.1 Animal Mass
There were no differences in starting or ending animal masses between treatment
groups, or across time in a given treatment (one-way-ANOVA). Three groups had
significant changes in animal mass during the course of the study as examined by paired
t-test: IR+PL animals euthanized at 2 (-2.5%) and 3 (-1.5%) weeks as well as IR+RIS
animals euthanized at one week (+2%) (Table 3.1).
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Table 3.1. Mean animal masses.

Week 1

Week 2

Week 3

% Ch

Initial

Final

NR+PL
IR+PL
IR+RIS

23.3 ± 0.2

23.4 ± 0.3

0.3

23.2 ± 0.5

23.0 ± 0.5

-0.9

22.5 ± 0.2

23.0 ± 0.3

2.0

NR+PL
IR+PL
IR+RIS

23.1 ± 0.2

23.0 ± 0.4

-0.5

23.1 ± 0.3

22.6 ± 0.3

-2.5

22.7 ± 0.4

22.7 ± 0.3

0.0

NR+PL
IR+PL
IR+RIS

22.9 ± 0.4

22.9 ± 0.5

-0.1

23.1 ± 0.4

22.7 ± 0.4

-1.5

22.8 ± 0.3

22.7 ± 0.3

-0.4

a

a

a

Notes: All data given as mean ± SEM in grams. a difference between initial and final
values (paired t-test p<0.05).

3.4.2 Bone Architectural Analyses
3.4.2.1 Proximal Tibia
Analysis of trabecular bone properties within treatments across time of the
proximal tibia identified no changes between baseline and non-irradiated control
(NR+PL) groups. Within irradiated (IR+PL) animals, there was a significant reduction in
BV/TV (-18%; Figure 3.1) and vBMD (-12%; Table 3.2) at week 3 relative to week 1.
Irradiated animals treated with risedronate (IR+RIS) showed a significant increase in
vBMD (+12%) at week 3 compared to week 2.
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Figure 3.1. Trabecular bone volume of proximal tibia.
Notes: * different from NR+PL within time point; + different from week 1 within
treatment; # different from week 2 within treatment (ANOVA p<0.05). % difference given
relative to NR+PL.

Table 3.2. Trabecular bone properties of proximal tibia from µCT.

Baseline
Week 1

Week 2

Week 3

vBMD
(mg HA/cm3)

Tb.N
(1/mm)

Tb.Sp
(µm)

Tb.Th
(µm)

101.6 ± 2.4

2.95 ± 0.11

343 ± 13.1

51.3 ± 1.1

NR+PL
IR+PL
IR+RIS

99.4 ± 4.0
85.5 ± 2.4
100.1 ± 2.6

NR+PL
IR+PL
IR+RIS

96.7 ± 3.3
78.1 ± 2.9
96.7 ± 2.7

NR+PL
IR+PL
IR+RIS

95.5 ± 2.4
75.4 ± 2.6
108.4 ± 2.0

b

b

b,c
b,d

2.82 ± 0.12
2.46 ± 0.07
2.84 ± 0.06
2.77 ± 0.07
2.44 ± 0.08
2.89 ± 0.08
2.61 ± 0.07
2.52 ± 0.10
2.81 ± 0.07

b

b

357 ± 16.5
411 ± 11.4
349 ± 9.4
362 ± 9.8
410 ± 13.8
352 ± 11.4
384 ± 10.5
400 ± 16.3
359 ± 10.1

b

b

54.5 ± 1.0
55.3 ± 0.9
52.8 ± 1.0
54.3 ± 1.5
52.5 ± 1.4
52.4 ± 1.0
54.4 ± 1.0
54.1 ± 1.5
53.6 ± 1.4

Notes: All data given as mean ± SEM. b different from NR+PL within time point.
c
different from week 1 within treatment. d different from week 2 within treatment
(ANOVA p<0.05).
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Within time points, irradiated animals (IR+PL) showed significant changes in:
BV/TV (-22%), Conn.Dens (-43%; Figure 3.2), SMI (+9%; Figure 3.3), vBMD (-14%),
Tb.N (-13%; Table 3.2), and Tb.Sp (+15%; Table 3.2) at 1 week; BV/TV (-25%),
Conn.Dens (-40%), vBMD (-19%), Tb.N (-12%) and Tb.Sp (+13%) at 2 weeks; and
BV/TV (-32%), Conn.Dens (-53%), SMI (+12%), and vBMD (-21%) at 3 weeks relative
to non-irradiated controls (NR+PL). Administration of risedronate (IR+RIS) increased
BV/TV (+21%), Conn.Dens (+36%), and vBMD (+13%) at 3 weeks relative to NR+PL.

Figure 3.2. Trabecular connectivity of proximal tibia.
Notes: * different from NR+PL within time point (ANOVA p<0.05).
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Figure 3.3. Structural model index of proximal tibia.
Notes: * different from NR+PL within time point (ANOVA p<0.05).

3.4.2.2 Distal Femur
Analysis within treatments across time identified significant changes in Tb.N (7%; Table 3.3) and Tb.Sp (+8%; Table 3.3) at 3 weeks in non-irradiated controls
(NR+PL) relative to baseline. Within irradiated-only animals (IR+PL), Tb.Sp (+6%) was
significantly higher at week 3 compared to week 1. At week 3, irradiated animals treated
with risedronate (IR+RIS) showed significant changes in Conn.Dens (+55%; Figure 3.5)
and SMI (-9%; Figure 3.6) relative to week 1, as well as BV/TV (+29%; Figure 3.4),
Conn.Dens (+55%), SMI (-8%), and vBMD (+29%; Table 3.3) relative to week 2.

34

Table 3.3. Trabecular bone properties of distal femur from µCT.
vBMD
(mg HA/cm3)

Baseline
Week 1

Week 2

Week 3

Tb.N
(1/mm)

49.0 ± 4.5
NR+PL
IR+PL
IR+RIS

41.0 ± 3.5
25.2 ± 2.5
54.2 ± 3.4

NR+PL
IR+PL
IR+RIS

43.7 ± 2.3
24.4 ± 2.9
47.5 ± 3.2

NR+PL
IR+PL
IR+RIS

39.6 ± 4.2
24.4 ± 2.8
61.4 ± 3.9

Tb.Sp
(µm)

3.21 ± 0.05

b
b

b

b
b,d

3.17 ± 0.06
2.95 ± 0.05
3.28 ± 0.06
3.07 ± 0.04
2.81 ± 0.04
3.21 ± 0.05
2.99 ± 0.05
2.81 ± 0.05
3.29 ± 0.06

b

b

a
b
b

Tb.Th
(µm)

311 ±

4.2

317 ±
341 ±
306 ±

6.3
5.5
5.5

326 ±
359 ±
313 ±

3.8
4.9
4.5

336 ±
360 ±
304 ±

5.5
5.9
5.5

36.9 ± 1.2

b

b

a
b,c
b

37.1 ± 1.4
34.6 ± 1.0
38.2 ± 1.3
37.1 ± 1.4
36.0 ± 1.2
37.1 ± 0.9
37.2 ± 1.3
34.9 ± 1.9
39.1 ± 1.1

Notes: All data given as mean ± SEM. a different from baseline within NR+PL.
b
different from NR+PL within time point. c different from week 1 within treatment.
d
different from week 2 within treatment (ANOVA p<0.05).

Figure 3.4. Trabecular bone volume of distal femur.
Notes: * different from NR+PL within time point. # different from week 2 within
treatment (ANOVA p<0.05). % difference given relative to NR+PL.

35

Within time points, irradiated animals (IR+PL) showed significant changes in:
BV/TV (-32%), vBMD (-39%), Tb.N (-7%), and Tb.Sp (+7%) at 1 week; BV/TV (-39%),
Conn.Dens (-67%), SMI (+15%), vBMD (-44%), Tb.N (-8%), and Tb.Sp (+10%) at 2
weeks; and BV/TV (-43%), Conn.Dens (-65%), SMI (+15%), vBMD (-38%), Tb.N (6%), and Tb.Sp (+7%) at 3 weeks relative to non-irradiated controls (NR+PL).
Risedronate treated animals (IR+RIS) showed significant changes in vBMD (+32%) at
week 1, and BV/TV (+50%), Conn.Dens (+134%), SMI (-10%), vBMD (+55%), Tb.N
(+10%), and Tb.Sp (-9%) at week 3 relative to non-irradiated controls (NR+PL).

Figure 3.5. Trabecular connectivity of distal femur.
Notes: * different from NR+PL with time point. + different from week 1 within
treatment. # different from week 2 within treatment (ANOVA p<0.05). % difference given
relative to NR+PL.
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Figure 3.6. Structural model index of distal femur.
Notes: * different from NR+PL with time point. + different from week 1 within
treatment. # different from week 2 within treatment (ANOVA p<0.05). % difference given
relative to NR+PL.

3.4.2.3 5th Lumbar Vertebra
Analysis within treatments across time identified significant changes in: BV/TV
(Figure 3.7) at weeks 2 (-9%) and 3 (-11%); SMI (Figure 3.9) at weeks 2 (+69%) and 3
(+83%); and vBMD (Table 3.4) at weeks 1 (-8%), 2 (-10%), and 3 (-10%) in nonirradiated animals (NR+PL) relative to baseline controls. Additionally, these animals
showed significant changes in Conn.Dens (+27%; Figure 3.8), SMI (+45%), and Tb.Th (6%; Table 3.4) at week 3 compared to week 1. Within irradiated animals (IR+PL),
significant changes in vBMD were identified at 2 (-8%) and 3 (-8%) weeks relative to 1
week. Irradiated animals treated with risedronate (IR+RIS) showed significant changes
in BV/TV (+7%) at week 3 compared to week 2.
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Figure 3.7. Trabecular bone volume of L5 vertebra.
Notes: $ different from baseline within NR+PL. * different from NR+PL within time
point. # different from week 2 within treatment (ANOVA p<0.05). % difference given
relative to NR+PL.

Figure 3.8. Trabecular connectivity of L5 vertebra.
Notes: * different from NR+PL within time point (ANOVA p<0.05).
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Analysis within time points revealed significant changes in: BV/TV (-9%) and
SMI (+70%) at 1 week; BV/TV (-15%), SMI (+48%), vBMD (-10%), Tb.N (-7%; Table
3.4), and Tb.Sp (+8%; Table 3.4) at 2 weeks; and BV/TV (-11%), Conn.Dens (-21%),
SMI (+34%), vBMD (-8%), Tb.N (-9%), and Tb.Sp (+10%) within irradiated animals
(IR+PL) relative to non-irradiated controls (NR+PL). Irradiated animals treated with
risedronate (IR+RIS) showed significant changes in: BV/TV (+15%), SMI (-48%),
vBMD (+15%), and Tb.Th (+7%) at 1 week; BV/TV (+14%), SMI (-48%), vBMD
(+12%), and Tb.Th (+6%) at 2 weeks; and BV/TV (+25%), SMI (-74%), vBMD (+15%),
and Tb.Th (+12%) at 3 weeks compared to non-irradiated controls (NR+PL).

Table 3.4. Trabecular bone properties of L5 vertebra from µCT.

Baseline
Week 1

Week 2

Week 3

vBMD
(mg HA/cm3)

Tb.N
(1/mm)

292.5 ± 5.4

6.63 ± 0.07

144 ±

1.5

45.3 ± 0.9

6.26 ± 0.08
6.25 ± 0.09
6.49 ± 0.12

154 ±
155 ±
146 ±

3.0
2.6
3.4

46.2 ± 0.5
45.7 ± 0.5
49.2 ± 0.6

149 ±
161 ±
145 ±

2.9
2.4
3.1

150 ±
164 ±
145 ±

3.7
3.9
2.8

NR+PL
IR+PL
IR+RIS

268.0 ± 7.7
259.8 ± 4.4
308.1 ± 5.0

a

NR+PL
IR+PL
IR+RIS

263.6 ± 5.2
238.6 ± 6.0
296.0 ± 4.4

a

NR+PL
IR+PL
IR+RIS

262.0 ± 5.7
239.9 ± 6.5
302.2 ± 3.8

a

b

b,c
b,c

b,c
b,c

6.46 ± 0.12
6.04 ± 0.07
6.51 ± 0.12
6.52 ± 0.14
5.96 ± 0.13
6.54 ± 0.10

Tb.Sp
(µm)

b

b

Tb.Th
(µm)

b

b

44.6 ± 0.7
43.7 ± 0.8
47.4 ± 0.5
43.2 ± 0.5
44.7 ± 0.5
48.5 ± 0.6

Notes: All data given as mean ± SEM. a different from baseline within NR+PL.
b
different from NR+PL within time point. c different from week 1 within treatment.
(ANOVA p<0.05).
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b

b

c

b

Figure 3.9. Structural model index of L5 vertebra.
Notes: $ different from baseline within NR+PL. * different from NR+PL within time
point. + different from week 1 within treatment (ANOVA p<0.05). % difference given
relative to NR+PL.

3.4.2.4 Femur Mid-diaphysis
Within non-irradiated controls (NR+PL), Ct.Po was significantly different at
weeks 1 (-25%) and 2 (-19%) when compared to the baseline control group. There were
no further differences between any groups within treatments or time points in BV, Ct.Po,
or pMOI (Table 3.5).
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Table 3.5. Cortical bone properties from µCT.
BV
(mm3) * 103

Ct.Po
(%)

pMOI
(mm4) * 103

216.7 ± 3.3

7.38 ± 0.36

323.8 ± 10.0

NR+PL
IR+PL
IR+RIS

226.0 ± 2.2

5.55 ± 0.22

223.2 ± 3.2

5.58 ± 0.14

333.6 ± 11.9

222.3 ± 2.6

5.86 ± 0.23

329.8 ±

8.1

NR+PL
IR+PL
IR+RIS

225.0 ± 2.3

5.95 ± 0.24

332.6 ±

6.0

216.6 ± 3.0

6.39 ± 0.28

323.3 ±

8.1

219.7 ± 2.7

6.60 ± 0.20

324.6 ±

8.7

NR+PL
IR+PL
IR+RIS

226.5 ± 3.4

6.61 ± 0.32

331.5 ± 10.9

219.6 ± 3.4

6.31 ± 0.27

324.7 ±

8.5

223.9 ± 3.2

6.58 ± 0.24

331.9 ±

9.5

Baseline
Week 1

Week 2

Week 3

a

a

333.0 ±

7.0

Notes: All data are given as mean ± SEM. a different from baseline within NR+PL
(ANOVA p<0.05).

3.4.3 Serum Chemistry
TRAP5b data from the baseline controls and non-irradiated animals within weeks
2 and 3 were found to be elevated (~37%) relative to non-irradiated controls from week
1. The differences were attributed to variability between the kits and equipment used.
The results from these groups were normalized to the week 1 data prior to statistical
comparison. No significant differences in TRAP5b concentration were found within
treatments across the duration of the study. Within time points, irradiated animals
(IR+PL) showed a significant elevation in concentration at week 1 (+21%), and irradiated
animals treated with risedronate (IR+RIS) showed significant reductions at week 1 (36%), week 2 (-35%), and week 3 (-37%) relative to non-irradiated controls (NR+PL)
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(Table 3.6). Analysis of serum osteocalcin concentration found no differences within
treatments or within any time point.

Table 3.6. Serum chemistry results.

Baseline
Week 1

Week 2

Week 3

NR+PL
IR+PL
IR+RIS

TRAP5b
(U/L)

Osteocalcin
(ng/ml)

6.60 ± 0.28

80.7 ± 11.6

8.88 ± 0.53

151.6 ± 40.7

10.71 ± 0.56

a

128.5 ± 19.5

5.66 ± 0.42

a

77.9 ± 18.1

NR+PL
IR+PL
IR+RIS

8.37 ± 0.88

NR+PL
IR+PL
IR+RIS

8.06 ± 0.58

110.7 ± 22.3

9.25 ± 0.57
5.43 ± 0.53

128.1 ± 24.3
a

83.0 ± 18.7

8.96 ± 0.87
5.07 ± 0.33

95.3 ± 20.1

112.1 ± 24.4
a

73.3 ± 10.7

Notes: All data are given as mean ± SEM. a different from NR+PL within time point
(ANOVA p<0.05).

3.5 Discussion
Exposure to ionizing radiation is known to have negative effects on the skeletal
system. In the present study, we quantified the effects of low energy X-rays on
trabecular and cortical bone properties at multiple skeletal sites and time points, and
examined the effectiveness of risedronate administration at preventing post-irradiation
bone atrophy. A single, whole-body exposure to X-rays was found to significantly
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deteriorate trabecular bone volume and micro-architecture as early as one week postexposure and elevate levels of serum bone resorption markers. Further, administration of
risedronate inhibited this degradation at all time points examined, indicating the observed
loss may be osteoclast-regulated.
Trabecular bone provides an important component to overall bone strength
(Keaveny, Morgan et al. 2001; Bouxsein 2005). The strength of trabecular bone depends
heavily on density and architecture (Currey 2001), so any reductions in properties may
adversely affect susceptibility to fracture. Under normal conditions, trabeculae are
structured as either parallel plates (SMI=0) or cylindrical rods (SMI=3). SMI has been
shown to have a negative correlation with bone volume (Hildebrand, Laib et al. 1999).
L5 contained the highest percentage of trabecular bone of the sites examined, and thus
had the lowest value of SMI. The bone volume of the proximal tibia and distal femur
were less than 1/3 that of the vertebra and were both largely composed of rod-like
trabeculae. The ratio of plates to rods remained relatively stable in these sites in nonirradiated animals, as did associated measures of bone volume (BV/TV) and density
(vBMD). However, in the case of L5, bone volume and density continually decreased,
and a number of trabeculae transitioned from plates to rods, although the overall plate-torod ratio remained high. This is expected, as skeletal properties have been shown to
deteriorate with age once skeletal maturity is reached (Halloran, Ferguson et al. 2002;
Glatt, Canalis et al. 2007).
Although trabecular bone volume is generally the strongest indicator of strength
(Hildebrand, Laib et al. 1999), connectivity plays a vital role in load distribution. Loss of
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individual struts and associated connectivity increases the likelihood of failure through
buckling of the remaining elements, greatly reducing the strength of the bone (Silva and
Gibson 1997). Trabecular number and spacing generally remained unchanged in nonirradiated animals, with the distal femur being the exception. Declines of less than 10%
at week 3 were seen in both parameters. Accordingly, connectivity density remained
stable in both the proximal tibia and distal femur, but was much less consistent within L5.
It has been suggested that remodeling of trabeculae from plates to rods may artificially
increase measures of connectivity (Campbell, Buie et al. 2008). This may account for the
inconsistency in connectivity within L5 at the early time points, as the upward trend in
SMI had begun to level out by the end of the third week.
Exposure to X-rays was found to affect many of the trabecular architectural
parameters at the tibia, femur, and L5. Substantial declines in bone volume and bone
mineral density occurred continually throughout the study. The majority of these
changes were present after the first week, indicating the mechanism for bone loss was
activated quickly following exposure. Negative changes in trabecular number and
spacing occurred early within the tibia and femur, as did the large reductions in overall
connectivity density at these sites. Within L5, the effects on trabecular number and
spacing occurred much later, along with the changes in connectivity density. Considering
the relatively small changes in bone volume and bone mineral density in L5 when
compared with the tibia and femur, the mechanism for bone loss may have a lower
affinity for regions of high bone mass in the short-term, or the process may take
significantly longer than at the lower density sites. Conversely, the structural model
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index of L5 decreased much more substantially than at the tibia and femur. This is
somewhat expected, as the individual struts within the tibia and femur were largely rodlike in structure prior to irradiation. L5 is composed of a much larger percentage of
plate-like trabeculae, and therefore has a greater potential for remodeling into rod-like
trabeculae.
As mentioned earlier, deterioration of trabecular bone properties has a negative
effect on overall bone strength (Currey 2001). Radiotherapy has been implicated in
fractures involving the ribs, clavicle, humerus, and hips (Howland, Loeffler et al. 1975;
Pierce, Recht et al. 1992; Grigsby, Roberts et al. 1995; Bliss, Parsons et al. 1996;
Mumber, Greven et al. 1997; Moreno, Clemente et al. 1999). Significant declines in
trabecular bone volume, bone mineral density, and associated measures of connectivity
were identified within one week of radiation exposure. These findings identify a
potential cause for the noted increases in fracture risk following radiation treatment. Loss
of bone volume and subsequent weakening of the trabecular framework may lead to
increases in fracture incidence.
At all time points examined, risedronate inhibited bone loss, identifying an
increase in bone resorption as the possible mechanism for radiation atrophy. Treatment
began immediately following irradiation, and the effects of risedronate were evident after
one week. Treated animals exhibited no changes in trabecular properties relative to
controls during the first two weeks of treatment at the proximal tibia and distal femur.
By the end of the third week, bone resorption was reduced enough to shift the balance
within the normal turnover mechanism toward formation, resulting in a net increase in
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trabecular properties. The mice exhibited substantially increased trabecular bone volume,
connectivity density, and bone mineral density. Trabecular plate-to-rod ratio was also
increased at the femur, although the overall ratio remained rod-like. Improvements in
trabecular number and spacing were also identified. The effects were much smaller
within L5, although changes were visible beginning at one week. Bone volume and bone
mineral density were increased while SMI was reduced as the trabeculae were remodeled
from rods to plates. Trabecular thickness was also affected, showing an increase at all
time points.
The geometric properties of cortical bone (cross-sectional area, moment of inertia,
etc.) are the primary contributors to overall bone strength (Augat and Schorlemmer
2006). Therefore, any changes in cortical bone properties as measured via microcomputed tomography may have a significant effect on susceptibility to fractures. Prior
studies have shown significant increases in cortical bone porosity and reductions in
strength following high-dose irradiation (Sugimoto, Takahashi et al. 1991; Nyaruba,
Yamamoto et al. 1998). In both cases, these changes occurred following a single, highdose exposure (greater than 10 Gy). Fractionation into doses less than 2 Gy mitigated the
negative effects on strength (Nyaruba, Yamamoto et al. 1998), indicating lower doses
may have no effect on cortical bone. More recent studies have found no changes in
cortical parameters following exposure to doses of 2 Gy or less (Hamilton, Pecaut et al.
2006; Bandstra, Pecaut et al. 2008). The results from the current study are consistent
with these findings, as there were no significant differences in cortical volume, porosity,
or polar moment of inertia between irradiated-only and non-irradiated animals. Further,
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risedronate administration has been shown to have minimal effects on measures of
cortical thickness and porosity (Dufresne, Chmielewski et al. 2003). Accordingly, no
changes were observed in any of the measured cortical parameters between irradiated
animals given risedronate and non-irradiated controls.
Of further interest were the observed differences in cortical porosity between
baseline animals and the non-irradiated controls from weeks 1 and 2. Baseline animals
exhibited relatively high values of porosity. It should be noted that the standard deviation
in these animals was higher than in any of the other study groups. This, coupled with the
lack of differences in polar moment of inertia and bone volume, indicate the porosity
variations may be due to random biological differences within the baseline animals, as
several samples exhibited porosity values over 20% higher than the mean.
Animal mass was used as an indicator of overall animal health throughout the
course of the study, as weight loss is a well-known side effect of exposure to ionizing
radiation. An overall reduction in body mass results in a reduction in loading on the
skeleton. According to Wolff’s Law, significant reduction in loading would likely lead to
decreased bone volume and trabecular micro-architecture. Irradiated-only animals at
weeks 2 and 3 showed significant losses of mass. In each case, the magnitude of the
changes was approximately 0.5 grams. Similarly, risedronate-treated animals showed
only an increase in mass at week 1. Despite these changes, there were no differences in
initial or final masses between individual groups, indicating the noted deterioration
following irradiation and subsequent maintenance with risedronate of trabecular bone
architectural properties were not due to changes in skeletal loading.
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The biological mechanisms leading to the observed radiation-induced bone loss
have yet to be fully explored. While past research has focused on the radiation effects on
osteoblasts and vasculature (Mitchell and Logan 1998; Okunieff, Wang et al. 1998; Gal,
Munoz-Antonia et al. 2000; Sakurai, Sawada et al. 2007), the present study indicates
radiation atrophy may be osteoclast-regulated. Elevated serum levels of tartrate-resistant
acid phosphatase (TRAP5b) were found at one week post-exposure in irradiated-only
animals, indicating an increase in the number of osteoclasts (Halleen, Tiitinen et al.
2006). Osteocalcin levels remained unchanged throughout the study. By the end of the
second week, TRAP5b levels were stabilized. This suggests a net increase in bone
resorption occurred within the first several days post-exposure. These findings are
consistent with the microCT results, as the majority of the measured changes in
trabecular volume and architecture occurred during the first week of the study.
Considering the effectiveness of risedronate, an early increase in osteoclast activity is a
likely contributor to radiation-induced bone loss.
In summary, exposure to a single, whole-body dose of X-rays produced
significant deterioration of trabecular bone volumetric and micro-architectural properties
in skeletally mature mice with no associated changes in cortical bone properties. Loss of
trabecular bone was identified at the proximal tibia, distal femur, and fifth lumbar
vertebra at all time points examined, with a large portion of the changes occurring within
the first week post-exposure. When considered with the increase in serum bone
resorption markers seen at one week with no changes in bone formation markers, an early
increase in osteoclast activity seems the likely the cause of radiation-induced bone loss.
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Risedronate was proven effective at preventing trabecular bone deterioration, identifying
a potential measure of preventing radiation-induced fractures. Further examination is
recommended to fully explore radiation effects on bone turnover and determine the most
appropriate and effective route for preventing fractures.
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CHAPTER 4 – CONCLUSIONS AND RECOMMENDATIONS

4.1 Summary
This research identified a substantial deterioration of trabecular bone microarchitectural properties following exposure to a whole-body dose of radiation. Measures
of trabecular volume, density, number, and structure were affected within one week of
irradiation at sites within both the appendicular and axial skeletons. Cortical bone
properties showed no effects from radiation. Serum concentrations of bone resorption
markers were elevated at one week post-irradiation. Bisphosphonate treatment prevented
trabecular bone loss at all sites examined and maintained associated architectural
properties.

4.2 Limitations and Recommendations
The radiation source used in the present study operates at an energy level several
orders or magnitude lower than those used in radiotherapy. Radiation effects on bone are
believed to be reduced when using sources operating at higher energy levels (Howland,
Loeffler et al. 1975; Mitchell and Logan 1998). Although the physics of low energy xrays is different, photon energy does not affect the biological response of normal tissue.
However, as bone is a dense material that has received little study by radiation biologists,
it is important to be cognizant of a potential energy effect. A clinical radiation source
should be used in future studies to eliminate any potential energy-level dependence of
bone effects.
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Typical radiotherapy regimens are localized to the tumor site and given in
fractionated doses (National Cancer Institute 2007). Future studies should involve a
larger cumulative dose given in fractions to a specific site to model a typical tumor
treatment cycle. This can be accomplished through the use of shielding and/or focusing
of the radiation beam using a clinical irradiator.
Risedronate is currently approved for treatment of glucocorticoid-induced and
post-menopausal osteoporosis as well as Paget’s disease. The prescribed oral dose for
osteoporosis patients is 5 mg/day, 35 mg/week, or 150 mg/month. Although the
pharmacokinetics of risedronate in mice are not fully understood, a dose of 70 µg/kg/day
given orally is considered comparable (Sefc, Broulik et al. 2007). Using a bioavailability
of 0.63% (Crandall 2001), this equates to an approximate subcutaneous dose of 0.5
µg/kg/day. The dose administered in the current study (30 µg/kg every other day) was
significantly larger, and more comparable (though still larger) to the dose prescribed to
Paget’s disease patients (30 mg/day oral, ~3 µg/kg/day subcutaneous). As such, the
sparing effects of the drug on bone loss were likely exaggerated when considered in
context with normal osteoporosis treatment regimens. The effects of smaller doses that
model those given osteoporosis patients should be examined in order to determine the
minimum threshold for efficacy.
Although the serum chemistry results indicate an increase in osteoclast activity,
the radiation effects on individual cells are not examined. Histological analysis is needed
to quantify and qualify the changes in bone cell structure and number. Additionally,
dynamic histomorphometry is recommended to quantify both radiation and drug-induced
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changes in bone formation and resorption rates. These data along with results from the
microCT analyses should be correlated with changes in whole bone strength as
determined via mechanical testing.
To more fully characterize the radiation effects on bone, both earlier and later
time point examinations are needed. The results from the present study indicate the
mechanism for bone loss is activated within the first week post-exposure. Earlier time
points should be studied to determine the timeline when the changes to bone cells
produce functional declines in bone architectural properties. Additionally, time points
after three weeks should be examined to determine if/when any natural bone loss
recovery occurs.
The results from this research have potential implications in the study of skeletal
changes resulting from spaceflight. In addition to the microgravity environment which is
known to cause reductions in bone mass (Lang, LeBlanc et al. 2004), astronauts are
exposed to multiple types of radiation, including protons and heavy ion particles (Todd
2003), which may increase the magnitude of bone deterioration. The effects of exposure
to these types of radiation should examined to determine if specific radiation types are
potentially more damaging to bone, and determine if any bone deterioration that is
measured can be effectively treated.

4.3 Conclusions
The results from this research support earlier findings within our laboratory of an
early increase in osteoclast activity following exposure to ionizing radiation. Trabecular
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bone deterioration can occur rapidly, leading to elevated levels of serum bone resorption
markers at one week post-irradiation. Bone formation appears unaffected in the shortterm. Anti-resorptive therapy is effective at preventing radiation-induced bone loss,
further supporting finds of increased osteoclast activity. The results from this study and
future studies incorporating the above recommendations will prove useful in determining
the most effective method of preventing fractures resulting from radiotherapy, and lead to
a higher quality of life for cancer survivors.
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Appendix A

Risedronate Dosing and Dilution

Using information provided by Procter and Gamble, a risedronate dose of 30 µg/kg given
every other day was chosen. The drug was received in dry form in vials containing 5 mg
samples.
1.

Five ml of sterile PBS was added to the dry sample within one vial. The solution
was then vortexed for an appropriate time to allow the compound to dissolve into
solution at a concentration of 1 mg/ml.

2.

Four milliliters of the solution was pipetted from the vial and placed in a sterile 5
ml tube (stock solution).

3. The concentration of the injected dose was determined as follows based on a
standard volume of 0.2 ml given to a 20 g animal:
𝜇𝑔
𝑘𝑔
1 𝑚𝑜𝑢𝑠𝑒
103 𝑚𝑔
𝑚𝑔
30
× 0.02
×
×
=
0.003
𝑘𝑔
𝑚𝑜𝑢𝑠𝑒
0.2 𝑚𝑙
106 𝜇𝑔
𝑚𝑙
4.

The injectable solution was then created from the stock solution through a series
of dilutions as follows:

1

𝑚𝑔
𝑚𝑔
× 𝐴 𝑚𝑙𝑠𝑡𝑜𝑐𝑘 = 0.1
× 4 𝑚𝑙
𝑚𝑙
𝑚𝑙
0.1
0.01

𝑚𝑔
𝑚𝑔
× 𝐵 𝑚𝑙𝐴 = 0.1
× 4 𝑚𝑙
𝑚𝑙
𝑚𝑙
𝑚𝑔
𝑚𝑔
× 𝐶 𝑚𝑙𝐵 = 0.003
× 4 𝑚𝑙
𝑚𝑙
𝑚𝑙
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𝐴 = 0.4 𝑚𝑙𝑠𝑡𝑜𝑐𝑘 + 3.6 𝑚𝑙𝑃𝐵𝑆
𝐵 = 0.4 𝑚𝑙𝐴 + 3.6 𝑚𝑙𝑃𝐵𝑆
𝐶 = 1.2 𝑚𝑙𝐵 + 2.8 𝑚𝑙𝑃𝐵𝑆

5.

The volume of solution given to each animal was determined from mass (21 g
animal received 0.21 ml, 22 g animal received 0.22 ml, etc).
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Appendix B

MicroCT Scanning and Analysis

Site

Threshold

Sigma

Support

Proximal tibia
Distal femur
L5 vertebra
Femur mid-diaphysis

365
225
220
260

1.2
0.8
0.8
0.8

2.0
1.0
1.0
1.0

Tube Setups

Tibia

Femur

L5 vertebra

1. Tibia: Samples were cut ~1/3 distance from proximal end and stacked in pairs for
4 levels (8 bones per tube). The direction of the proximal end was alternated
within each level. Foam was used for support and separation. P denotes the
proximal end.
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2. Femur: Samples were placed within circular foam discs as shown with the distal
end towards the bottom. Three discs were placed within the tube for scanning, for
a total of 12 bones per tube. X denotes a marker used for identification.
3. L5: Samples were placed as shown in pairs for 2 levels (4 per tube), alternating
the direction of the ribs within each level. Foam was used for support and
separation. R denotes the position of the ribs.
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